NCT02005315View on ClinicalTrials.gov

A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

October 31, 2017

Study Completion Date

November 30, 2017

Conditions
Pancreatic CancerStage IV Pancreatic Cancer
Interventions
DRUG

Vantictumab

Administered intravenous (IV) infusion.

DRUG

Nab-Paclitaxel

Nab-Paclitaxel will be administered by intravenous (IV) infusion.

DRUG

Gemcitabine

Gemcitabine will be administered by intravenous (IV) infusion.

Trial Locations (5)

19111

Fox Chase Cancer Center, Philadelphia

37232

Vanderbilt University Medical Center, Nashville

46202

Indiana University Simon Cancer Center, Indianapolis

80045

University of Colorado Hospital Anschutz Cancer Pavillion, Aurora

90033

USC/Norris Comprehensive Cancer Center, Los Angeles

Sponsors
All Listed Sponsors
lead

OncoMed Pharmaceuticals, Inc.

INDUSTRY